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Abstract
Purpose To evaluate macular function and structure
in patients with diabetic macular edema prior to, as
well as 3 and 6 months after intravitreal ranibizumab
treatment.
Patients and methods Seventeen eyes of 17 patients
with type 2 diabetes mellitus and diabetic macular
edema (DME) were treated with intravitreal injections
of 0.5 mg ranibizumab. Prior to the first injection, as
well as after 3 and 6 months, the following examina-
tions were performed: assessment of distance best-
corrected visual acuity (log MAR), perception of
metamorphopsia (M-Chart), slit lamp examination of
the anterior and posterior segment of the eye (Volk
90D lens), evaluation of the retinal and choroidal
circulation (fluorescein angiography), assessment of
the structure and thickness of the macula (OCT), as
well as evaluation of the macular function (PERG and
mfERG).
Results We observed that ranibizumab significantly
improved visual acuity after 3 and 6 months from the
beginning of the treatment, which was a consequence
of reduced macular edema and vascular leakage.
There was a statistically significant decrease in
metamorphopsia frequency at month 3; however, at
month 6 it was a statistically insignificant when
compared to the baseline. The results of electrophys-
iological examinations revealed no improvement in
ranibizumab-treated patients.
Conclusion Improvement of visual acuity and reduc-
tion in macular thickness were maintained up to the
6-month follow-up. The results of electrophysiologi-
cal examinations revealed that ranibizumab injections
tend to stabilize bioelectrical macular function of the
outer, middle and inner retinal layers, which was
impossible to recognize on the basis of visual acuity
and OCT. Therefore, the electrophysiological exam-
inations should be used as an additional objective tool
for the evaluation of the anti-VEGF treatment effec-
tiveness in DME.
Keywords Diabetic macular edema (DME) 
Ranibizumab  OCT  PERG  mfERG
Introduction
Diabetic retinopathy (DR) is a leading cause of vision
loss in working-age patients around the world, and
diabetic macular edema (DME) is its major vision-
threatening complication [1–3]. The results of many
studies indicate that one-fourth of patients with DR
suffer from DME [4]. Therefore, with increasing
number of new cases of type 2 diabetes each year,
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DME may become a significant public health issue.
The results of the Early Treatment Diabetic Retinopa-
thy Study (ETDRS) demonstrated that focal/grid
photocoagulation of DME might reduce the risk of
moderate visual loss by approximately 50 % and it has
been established as the gold standard treatment [5].
However, there are many cases where it carries a
significant risk, or efficient laser treatment could not
be performed due to diffuse macula edema. In the
aqueous humor of diabetics with DME, increased level
of the vascular endothelial growth factor (VEGF)—a
significant blood–retinal barrier breakdown media-
tor—was observed, which led to the hypothesis that
alternative or adjunct therapies using VEGF inhibitors
could be beneficial in reversing vision loss from
macular edema [6, 7]. The current standard methods
for evaluating the effectiveness of the anti-VEGF
treatment are visual acuity (VA) and optical coherence
tomography (OCT). Visual acuity indirectly provides
information about foveal function, while OCT reveals
only structural changes of the macula. That is why we
decided to also provide information about retinal and
choroidal circulation abnormalities (fluorescein
angiography—FA) and the macular function (pattern
and multifocal electroretinograms—PERG and
mfERG) before and after intravitreal anti-VEGF
treatment. The results of the electrophysiological
examinations contribute comprehensive information
about macular function in the course of DME because
PERG explores mostly ganglion cells’ function (the
inner layer of the retina), while mfERG explores
bipolar cells’ and cone photoreceptors’ (the middle
and outer layers). Moreover, the electrophysiological
examinations provide greater information about the
macular function, while VA corresponds to only 1
degree field of vision. According to our best knowl-
edge, there are only 2 studies in the literature
describing PERG/mfERG recordings in the DME
eyes treated with ranibizumab [8, 9] and our study for
the first time illustrates inner and outer macular
function changes before, as well as 3 and 6 months
after the beginning of intravitreal treatment.
Patients and methods
Seventeen eyes of 17 patients (8 males, 9 females)
aged 65 ± 10 years with type 2 diabetes mellitus and
DME were treated with intravitreal injections of
0.5 mg ranibizumab. The mean time of diabetes
mellitus was 17 ± 10.5 years. At baseline, the mean
hemoglobin A1C ± SD was 7.56 % ± 1.94. Exclu-
sion criteria were as follows: focal/grid laser treatment
within 3 months, intraocular injection of steroid
within 3 months, intraocular injection of a VEGF
antagonist within 2 months, eccentric fixation, bad
cooperation and potential contributing causes to
reduced macular function other than DME, for exam-
ple glaucoma or significant cataract. The first 3
intravitreal injections of 0.5 mg/0.1 ml ranibizumab
were obligatory performed every 4 weeks. The deci-
sions about additional injections were made up to
6 months. The therapy was not continued when the
thickness of the fovea reached B225 lm and BCVA
C79 letters, and was restarted when the thickness of
the fovea increased of at least 50 lm or was a BCVA
reduction in 5 letters and drop below 74 letters. Prior to
the first injection, as well as after 3 and 6 months, the
following examinations were performed: assessment
of distance best-corrected visual acuity (DBCVA) (log
MAR), perception of metamorphopsia (M-Chart), slit
lamp examination of the anterior and posterior
segment of the eye (Volk 90D lens), evaluation of
the retinal and choroidal circulation (FA), assessment
of the structure and thickness of the macula (Cirrus
HD-OCT, Carl Zeiss Meditec, Dublin, CA, USA), as
well as evaluation of the macular function—PERG
and mfERG (Roland Consult, Germany).
All parameters of PERG and mfERG were consis-
tent with the current International Society for Clinical
Electrophysiology of Vision (ISCEV) Standards [10,
11]. The electrodes used for recordings were as
follows: active electrode—thread DTL electrode
positioned above the upper margin of the lower eyelid
in contact with the cornea, and reference electrode—
gold disc electrode placed on the skin near the
ipsilateral outer canthus of the examined eye and
ground gold disc electrode placed on the forehead
(Fpz). The acceptable electrode impedances were
below 5 kX.
Pattern electroretinogram
The examination was performed with appropriate
optical correction for a distance of 0.5 meters and
without pupil dilatation, which ensured good retinal
image quality. During the examination, monocular
stimulation and central fixation were used. Stimulus
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parameters were as follows: black and white reversing
checkerboard with a check size of 1, luminance of the
white elements of 120 cd/m2, and contrast between
black and white squares of 97 %. Parameters of the
recording system were as follows: amplifiers sensitiv-
ity: 20 lV/div; filters: 1–100 Hz; notch filters: off;
sweep time: 250 ms (time base: 25 ms/div); and
artifact reject threshold: 25 % (for the amplifiers
range ±100 lV). Two trials of 100 artifact-free
sweeps for each eye were obtained and averaged off-
line. The analysis included measurements of the
amplitude and the peak time of P50 wave, the
amplitude of N95 wave, as well as N95/P50 ratio.
Multifocal electroretinogram
The examination was performed with appropriate
optical correction for a distance of 30 cm, and
patient’s pupils were maximally dilated ([6 mm)
with 10 % Neosynephrine. During the examination,
monocular stimulation and central fixation were used.
Stimulus parameters were as follows: a black and
white matrix of 61 scaled hexagons (distortion factor
equal to 4) displayed in the 50 field of vision,
luminance for white elements of 100 cd/m2, and the
contrast between black and white hexagons of 97 %.
Parameters of the recording system were as follows:
amplifiers sensitivity: 20 lV/div; filters: 10–300 Hz;
notch filters: off; plots time: 83 ms; and artifact reject
threshold: 8 % (for the amplifiers range ±100 lV).
Six cycles were averaged off-line including digital
smoothing (29), software reduction in line interfer-
ence and manual correction, if necessary, applied to
the automatic cursors placement. The analysis
included response density (the response amplitude
divided by the retinal area—nV/deg2) and peak time of
the P1-wave in ring 1 (R1) and ring 2 (R2), which
correspond to the foveal and parafoveal retinal area,
respectively.
All subjects participating in this study gave their
informed written consent. The project was approved
by the Ethics Committee of the Pomeranian Medical
University.
The Shapiro–Wilk test was used to evaluate the
normality of distribution of analyzed parameters. The
Student t test was used for the normal and Wilcoxon
signed-rank test for non-normal distributed data. To
address the problem of multiple comparisons, the false
discovery rate (FDR) methodology was used.
Corrected probabilities are presented in the manu-
script. The p value \0.05 was considered as
significant.
Results
During 6-month follow-up time, 47.1 % (8/17) eyes
required only 3 consecutive ranibizumab injections,
35.3 % (6/17) eyes required 4 injections, and 17.6 %
(3/17) eyes required 5 injections.
The progression from the non-proliferative to the
proliferative retinopathy occurred in 1 eye (5.6 %)
despite appropriate anti-VEGF therapy at this time.
Distance best-corrected visual acuity
The mean DBCVA at the baseline was equal to
0.62 ± 0.28 (log MAR scale) and improved signifi-
cantly to 0.4 ± 0.22 (p = 0.004) after 3 months.
Between third and sixth month DBCVA slightly
decreased to 0.46 ± 0.24, but this result was statistical
insignificant compared to mean DBCVA at month 3.
However, after 6 months from the baseline improve-
ment DBCVA was still statistically significant com-
pared to baseline (p = 0.049). The results of DBCVA
examinations are presented in Fig. 1.
Perception of metamorphopsia
At the baseline, 15 from 17 (88.2 %) patients
complained of metamorphopsia in the eye recruited
to intravitreal ranibizumab treatment. Distribution of
metamorphopsia according to M-Chart examination
was as follows: 10 patients—0, 1 patient—0.3, 1
patient—0.4, 2 patients—1.1 and 1 patient—2.
After 3-month follow-up, only 7 patients (41.2 %)
reported metamorphopsia and distribution of meta-
morphopsia was: 5 patients—0 and 2 patients—0.2.
The result was statistically significant (p = 0.04).
However, after 6 months the number of patients with
metamorphopsia increased to 12 (70.6 %), which was
statistically insignificant in comparison with the
baseline (p[ 0.05). Distribution of metamorphopsia
after 6 months from the beginning of the intravitreal
treatment was as follows: 9 patients—0, 2 patients—
0.3 and 1 patient—0.6. Insightful analysis revealed
that 2 patients, who did not report metamorphopsia at
the baseline, had significant macular edema (the mean
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foveal thickness was 705.5 lm, and the parafoveal
thickness was 572 lm in OCT) and their DBCVA was
almost the same as in the metamorphopsia present
group (logMAR 0.63 vs. 0.62). This might suggest that
all patients at the baseline reported metamorphopsia,
but these 2 patients did not understand or do not
perform the M-Chart examination properly due to the
low quality of vision. For this reason, it may be
assumed that all patients reported metamorphopsia at
the baseline. Figure 2 presents the percentage of
patients reporting metamorphopsia at 6-month follow-
up. Statistical analysis of the relationship between
metamorphopsia and the other tests’ results was
performed at third and sixth month. As it was
expected, after 3- and 6-month follow-up the non-
metamorphopsia group had better DBCVA P50 and
N95 amplitudes of PERG, as well as the mean P1-
response density in R1 and R2 in mfERG. However,
statistical analysis has limited value due to small
groups of patients in comparison. Therefore, these






















Fig. 1 Results of DBCVA in eyes of patients with DME at the baseline, 3 and 6 months after beginning treatment with intravitreal
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Fig. 2 Percentage of patients reporting metamorphopsia at the baseline, 3 and 6 months after beginning treatment with intravitreal
ranibizumab injections. ns not significant (p[ 0.05)
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Optical coherence tomography
After 3 months from the first ranibizumab injection,
there was a significant decrease in the mean foveal
thickness (FT) from 542 ± 136 lm to 325 ± 68 lm
(p\0.001).After 6 months,meanFT slightly increased
to 378 ± 148 lm compared to result in the thirdmonth,
but this was statistically insignificant (p = 0.12). How-
ever, after 6 months decrease in the mean FT was still
statistically significant compared to baseline (p = 0.01).
The results of the parafoveal thickness were changing
similarly to FT—the baseline: 492 ± 84 lm, third
month: 364 ± 36 lm (p = 0.001), sixth month:
399 ± 96 lm (p = 0.004 compared to the baseline).
The results of foveal and parafoveal thickness during
6-month follow-up are presented in Fig. 3.
Fluorescein angiography (FA)
At baseline, a massive leakage of dye, corresponding
to the diabeticmacular edema,was seen in 100 % (17/17)
eyes. AF results 4 weeks after third anti-VEGF injec
tion showed no dye leakage only in 2 eyes (11.8 %)
and reduced the intensity or the area covered by
leakage of dye in 4 eyes (23.5 %). In the other eyes,
despite improvement of DBCVA and reduction in the
macular thickness in OCT, the image of a leak in FA
remained unchanged. Similar results were obtained in
FA performed 6 months after initiation of anti-VEGF
therapy, in which no evidence of leakage of dye in the
macular area was visible in 3 eyes (17.7 %) and a
significant reduction in the intensity or the area
covered by a leakage in 4 eyes (23.5 %). The examples
of the fundus color photography, FA and OCT results
of the patient’s eye with DME at the baseline as well as
at the 3- and 6-month follow-up are presented in
Fig. 4.
Pattern electroretinogram
The mean P50 amplitude at the baseline was equal to
2.23 ± 1.19 lV and slightly decreased after 3 (1.98 ±
0.92 lV, p[ 0.05) and 6 months (1.78 ± 1.13 lV,
p[ 0.05). The mean P50 peak time was equal to
57.1 ± 8.7 ms and remained almost unchanged during
the whole examinations of the follow-up (56.5 ±
5.8 ms after third month, 57.7 ± 6.0 ms after the sixth
month, p[ 0.05). After 3- and 6-month follow-ups, the
mean P50 amplitude, aswell as themean P50 peak time,
did not significantly differ in comparison with the
baseline. ThemeanN95 amplitude changed similarly to
P50 amplitude—the baseline: 3.19 ± 1.81 lV, third
month: 2.96 ± 1.35 lm (p[ 0.05), sixth month:
2.56 ± 1.49 lm (p[ 0.05 compared to the baseline).
Also, N95/P50 amplitude ratio did not significantly
change during the follow-up. The results of the PERG
are summarized in Fig. 5. At baseline, 14/17 eyes
demonstrated reduced amplitudes of P50 and N95
waves in comparison with norms defined in our
laboratory for patients above 50 years old as mean ±
2SD (P50 = 3.2–11.3 lV; N95 = 4.8–15.7 lV). On
this basis, we decided to divide retrospectively patients
Table 1 The relationship between perception of metamor-
phopsia and visual acuity, OCT and electrophysiological tests’
(PERG and mfERG)
M (-) group M (?) group p
3rd month
DBCVA 0.37 0.45 ns
OCT
FT 314.6 339.3 ns
PFT 353.4 379.8 ns
PERG
A P50 2.2 1.7 ns
A N95 3.2 2.6 ns
mfERG
P1–R1 44.4 32.3 ns
P1–R2 21.0 14.4 ns
6th month
DBCVA 0.37 0.50 ns
OCT
FT 338.5 390.0 ns
PFT 379.0 405.3 ns
PERG
A P50 2.2 1.7 ns
A N95 2.9 2.5 ns
mfERG
P1–R1 40.4 37.5 ns
P1–R2 18.5 12.2 ns
The results are presented as a mean value
M (-) group patients without metamorphopsia, M (?) group
patients with metamorphopsia, DBCVA distance best-corrected
visual acuity, OCT optical coherence tomography, FT foveal
thickness, PFT parafoveal thickness, PERG pattern
electroretinogram, A P50 P50 wave amplitude, A N95 N95 wave
amplitude, mfERG multifocal electroretinogram, P1-R1 P1-
response density in ring 1, P1-R2 P1-response density in ring 2
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into two groups: first with normal PERG and second
with abnormal PERG. The level of HbA1c was almost
the same in normal and abnormal PERG group (7.2 vs.
7.6 mg %, respectively). In the normal PERG group,
the baseline visual acuity was better than in the
abnormal PERG group (0.52 vs. 0.64 logMAR), but
foveal and parafoveal thicknesses had similar values
(551 vs. 540 and 500 vs. 491 lm, respectively). After
the 3-month follow-up, the normal PERG group gained
on average 15 letters on ETDRS chart, while the
abnormal PERGgroup only 10.At this point of time, the
foveal thickness was also lower in the normal PERG
group in comparison with the abnormal PERG group
(275 vs. 335 lm), while parafoveal thickness was
almost the same like in both groups group (371 vs.
363 lm). After the 6-month follow-up, the normal
PERGgroupVAwas still 15 letters better in comparison
with the baseline, while the abnormal PERG group
maintained a result of only 6 letters better visual acuity.
At the end point of the study, the foveal thickness was
also better in the normal PERG group in comparison
with the abnormal PERGgroup (342 vs. 386 lm),while
parafoveal thicknesswas almost the same in bothgroups
(401 vs. 399 lm). On the basis of these results, it is
reasonable to suppose that normal PERG results prior to
ranibizumab treatment may be an indicator for its better
6-month effectiveness. However, further research is




































Fig. 3 Results of OCT examinations in eyes of patients with DME at the baseline, 3 and 6 months after beginning treatment with
intravitreal ranibizumab injections. Data are presented as mean and standard deviation. ns not significant (p[ 0.05)
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Multifocal electroretinogram
The mean P1-response density in R1 was equal to
31.4 ± 17.6 lV. After 3-month follow-up, it
increased to 39.4 ± 19.0 lV; however, the difference
was statistically insignificant. Instead of intravitreal
ranibizumab treatment, the mean P1-response density
in R1 at month 6 was almost the same as at the baseline
(34.3 ± 26.7 lV, p[ 0.05). The mean P1-response
density in R2 at the baseline was equal to
Baseline: VA – 0.54 logMAR
3rd month: VA – 0.2 logMAR
6th month: VA – 0.24 logMAR
Fig. 4 Examples of the fundus color photography, FA andOCT
results of the patient’s eye with DME at the baseline, as well as
at the 3- and 6-month follow-up. At baseline, FA revealed a
massive leakage of dye, corresponding to the diabetic macular
edema seen on OCT scan and color photography. After
3 months of treatment, no dye leakage was visible in macular
region and OCT scan showed reduction in macular thickness.
However, after 6 months of follow-up an increase in dye
leakage in FA and macular thickness in OCT was revealed


























































Fig. 5 Results of the PERG
obtained in eyes of patients
with DME at the baseline, 3




presented as mean and
standard deviation. ns not
significant (p[ 0.05)
118 Doc Ophthalmol (2016) 132:111–122
123
12.0 ± 6.4 lV. In the third month, this density
slightly increased to 18.2 ± 7.8 lV (p[ 0.05). How-
ever, as P1-response density in R1, it decreased to
almost the same value as at the baseline after 6-month
follow-up (12.9 ± 5.1 lV, p[ 0.05). After 3- and
6-month follow-up, the mean P1-peak time (R1 and
R2) also did not differ significantly in comparison with
the baseline. The results of the mfERG are summa-
rized in Fig. 6. The example of PERG and mfERG
results from the one eye of one patient in comparison
with OCT and VA during the 6-month follow-up is
shown in Fig. 7. At baseline, 15/17 eyes demonstrated
reduced P1 amplitudes’ densities in R1 and R2 in
comparison with norms defined in our laboratory
for patients above 50 years old as mean ± 2SD (P1 =
62.27–130.89 nV/deg2; P2 = 30.21–72.24 nV/deg2).
Dividing the patients into two groups (normal and
abnormal mfERG) revealed that patients with P1
amplitude within normal limits had much better
DBCVA (0.44 logMAR) and foveal/parafoveal thick-
nesses (403/431 lm) than patients with abnormal
mfERG results (0.64 logMAR, 560/500 lm, respec-
tively). Although normal mfERG group gained fewer
letters after 3 months of ranibizumab therapy in
comparison with the abnormal mfERG group (5 vs.
12 letters), their DBCVA was slightly better at third
month (0.34 vs. 0.40) and more stable in comparison
with the abnormal mfERG group (0.36 vs. 0.48 at sixth
month). The results of foveal/parafoveal thicknesses
changed similarly to DBCVA results, with greater
reduction in the abnormal mfERG group in the third
month, but clearer stabilization between third and
sixth month in normal mfERG group. Similarly to
PERG results, mfERG examinations showed a ten-
dency for better response to intravitreal ranibizumab
treatment in eyes with normal P1 amplitudes’ densities
in R1 and R2 at baseline, but further research on the
higher amount of eyes is needed to confirm these
findings.
Discussion
According to our best knowledge, the present study for
the first time described many aspects of the intravitreal
ranibizumab treatment effectiveness. We observed
that ranibizumab significantly improved visual acuity
after 3 and 6 months from the beginning of the
treatment, which was a consequence of reduced
macular edema and vascular leakage. The results of
previous studies concerning the relationship between
visual acuity or macular thickness and intravitreal
ranibizumab treatment confirm our findings [8, 12–15]
even though there were some differences in frequency
of ranibizumab injections and macular photocoagula-
tion was applied if eligible. We also observed that
there was a statistically significant decrease in meta-
morphopsia frequency at month 3 in ranibizumab-
treated patients. However, after 6 months of intravit-
real ranibizumab treatment, the frequency of meta-
morphopsia was statistically insignificant compared to
baseline. This is probably a result of increased foveal
and parafoveal thickness, which even though was
significantly reduced at month 6 when compared to
baseline, it was still outside the normal limits. In the
available literature, we did not find any reports about
the relationship between intravitreal ranibizumab
treatment and AF results. Although ranibizumab
seems to seal a blood–retinal barrier, we observed
reduction or no dye leakage in less than half of treated
eyes. The results of electrophysiological examinations
(PERG and mfERG) revealed no improvement in
ranibizumab-treated patients. The mfERG stimuli
location and anatomic area of R1 (0.0–2.3) corre-
sponded roughly to the fovea and of R2 (2.3–7.4) to
the parafovea and partially to the perifovea. The
difference in response in the fovea and parafovea
might be a result of the predominance of the functional
over structural changes in the latter. The decrease in
the macular edema resulted in the enhancement of
synaptic connectivity at month 3. Unfortunately, this
positive effect was not maintained at month 6, which
was probably a result of macular edema increase
detected in OCT. The latest mfERG study of Holm
et al. [8] also did not reveal improvement of macular
function 3 months after beginning of the intravitreal
treatment. Although PERG is widely used as a macular
function index, its visual stimulus activates large
retinal area. Probably as a result of the lower
sensitivity of small areas function change, we did
not observe any significant changes in PERG
responses in contrast to mfERG. Up to date, we found
only one study in the literature [9], which has
evaluated functional effects of ranibizumab therapy
with both electrophysiological examinations—PERG
and mfERG. Consistently with our results, Comyn
et al. [9] observed a small decrease in P50 amplitude in
months 3 and 6, whereas P50 peak time remained
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Fig. 6 Results of mfERG
obtained in eyes of patients
with DME at baseline and 3
and 6 months after
beginning treatment with
intravitreal ranibizumab
injections. ns not significant
(p[ 0.05)
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almost unchanged. Also, N95 amplitude did not
change significantly during follow-up. Although
authors also performed mfERG in ranibizumab-
treated patients, results are presented only after 1 year
of treatment, which make a comparison with our
results not possible.
Conclusion
In the present study, improvement in visual acuity and
reduction in macular thickness were maintained up to
6-month follow-up. However, results of electrophys-
iological examinations indicated on the significant and
persistent dysfunction of the macula in our patients
with DME. They revealed that ranibizumab injections
tend to stabilize the bioelectrical macular function of
the outer, middle and inner retinal layers, which is
impossible to be recognizing on the basis of VA and
OCT. Therefore, the electrophysiological examina-
tions should be used as an additional objective tool for
the evaluation of the anti-VEGF treatment effective-
ness in DME.
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